Medically reviewed by Reza Samad, MD Key Takeaways Cystic fibrosis treatment requires airway clearance techniques to remove ...

Among pediatric and adult patients with cystic fibrosis, the average number of chronic respiratory therapies used fell after ...

Cystic fibrosis affects many parts of the body, but its effects on the lungs can be especially harmful. Cystic fibrosis is a chronic and progressive condition that causes the mucus in your lungs to be ...

Vertex Pharmaceuticals’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today, Vertex’s portfolio of blockbuster CF products spans multiple ...

WASHINGTON (AP) — Federal health regulators have questions about the benefits of an experimental combination drug for cystic fibrosis, including whether the addition of a second drug ingredient adds ...

SPL84 is administered directly into the lungs where it is taken up by the cells and is expected to drive the production of fully functional CFTR proteins. The Food and Drug Administration (FDA) has ...

The US saw several new and expanded FDA indications this year. The top 5 most-read FDA approvals on AJMC.com included 4 novel ...

A cystic fibrosis vest is a therapeutic tool. When worn, it provides compressions similar to manual chest percussions. Wearing the vest can help loosen sticky secretions so that a person can more ...

Vertex Pharmaceuticals has reached a pricing deal for its cystic fibrosis drugs with the National Health Service in England, ending a yearslong campaign by patients to secure access to the medicines.

Boston-based Vertex Pharmaceuticals is in a dispute with Canadian officials over access to its cystic fibrosis drugs, STAT reported. The dispute focuses on three of Vertex’s drugs, Kalydeco, Orkambi ...

Vertex Pharmaceuticals, known for its line of cystic fibrosis drugs, has entered the gene editing space with a new $105 million deal with CRISPR Therapeutics. Cystic fibrosis has become the poster ...